



Published in final edited form as:

Int J Pharm. 2011 October 10; 418(1): 142–148. doi:10.1016/j.ijpharm.2011.01.010.

In vitro-In vivo Correlation: Perspectives on Model Development

Ying Lu¹, Sungwon Kim¹, and Kinam Park^{1,2,*}

¹Department of Pharmaceutics, Purdue University, West Lafayette, IN 47907, USA

²Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA

Abstract

In vitro – *in vivo* correlation (IVIVC) allows prediction of the *in vivo* performance of a drug based on the *in vitro* drug release profiles. To develop an effective IVIVC, the physicochemical and biopharmaceutical properties of the drug as well as the physiological environment in the body must be taken into consideration. Key factors include drug solubility, pKa, drug permeability, octanol-water partition coefficient and pH of environment. In general, construction of an IVIVC involves three stages of mathematical manipulation: construct a functional relationship between input (*in vitro* dissolution) and output (*in vivo* dissolution); establish a structural relationship using data collected; parameterize the unknowns in the structural model. Some key mathematical relationships used in IVIVC development are presented. The establishment of an effective IVIVC has important implications in quality control and regulatory compliance.

1. Introduction

An *in vitro* – *in vivo* correlation (IVIVC) is defined by the U.S Food and Drug Administration (FDA) as a predictive mathematical model describing the relationship between the *in vitro* property of an oral dosage form and relevant *in vivo* response. Generally the *in vitro* property is the rate or extent of drug dissolution or release, while the *in vivo* response is the plasma drug concentration or amount absorbed (FDA, 1997). An important objective of pharmaceutical product development is to gain better understanding of the *in vitro* and *in vivo* drug performances. Through the successful development and application of an IVIVC, *in vivo* drug performance can be predicted from its *in vitro* behavior. The establishment of a meaningful IVIVC can provide a surrogate for bioequivalence studies, improve product quality, and reduce regulatory burden. Since the pioneering works of Edwards (Edwards, 1951) and Nelson (Nelson, 1957) in correlating aspirin and theophylline dissolution rates with their respective *in vivo* appearances following oral administration, IVIVC has gained increasingly more significance in the pharmaceutical product development field. In particular, the emergence of new lipophilic drug candidates with low aqueous solubility demands special considerations during IVIVC model development.

The objective of the present review is to examine the various factors that need to be considered in the development of an IVIVC, including physicochemical factors,

© 2011 Elsevier B.V. All rights reserved

*Correspondence to: Professor Kinam Park Department of Biomedical Engineering 206 S. Martin Jischke Drive West Lafayette, IN 47907 Tel: +1-765-494-7759 Fax: +1-765-497-7290 kpark@purdue.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

biopharmaceutical factors, and physiological factors. We will discuss general approaches to developing an IVIVC. In particular, the steps associated with the construction of an IVIVC including modeling and data analysis will be addressed in detail. Lastly, the various applications of a meaningful IVIVC will be briefly described.

2. Considerations in IVIVC development

While it is widely recognized that correlations exist between *in vitro* drug dissolution and *in vivo* drug absorption, limited progress has been made toward the development of a comprehensive model capable of predicting *in vivo* drug absorption based on dissolution. This is due to the existence of a complex array of factors that contribute to the process of drug dissolution and absorption. In general, these factors can be classified into three groups; physicochemical factors, biopharmaceutical factors, and physiological factors. In order to develop a model that can demonstrate good correlation between *in vitro* drug dissolution and *in vivo* drug absorption, these factors have to be taken into consideration.

2.1. Physicochemical Properties

Physicochemical properties play a major role in predicting the *in vivo* absorption of drug candidates. For almost all drugs administered orally, dissolution is a prerequisite to drug absorption and clinical efficacy. Dissolution is dependent on several physicochemical properties, including solubility, pH dependency, salt forms, and particle size. A classical mechanistic equation that attempts to model dissolution is the Noyes-Whitney dissolution equation given by equation 1, which incorporates several of the physicochemical factors mentioned before.

$$\frac{dM}{dt} = \frac{D \times S \times (C_s - C_b)}{h} \quad (1)$$

In this equation, M is the amount of the drug dissolved, t is time, D is the diffusion coefficient of the drug in the liquid, unstirred boundary layer surrounding the dissolving drug particle, S is the surface area of drug particle, h is the diffusion layer thickness, and C_s and C_b represent drug solubility and drug concentration in the bulk medium at time t , respectively. The Noyes-Whitney equation describes dissolution rate as a function of the change in drug concentration over time. If the sink condition is assumed, equation 1 can be transformed into the following form:

$$\frac{dM}{dt} = \frac{D \times S \times C_s}{h} \quad (2)$$

where C_s is approximated by the solubility of the drug substance. This concurs with our previous statement that the rate of dissolution is dependent on solubility. Although the Noyes-Whitney equation is a useful approach to model dissolution, it cannot be utilized to describe all types of dissolution data and may not apply in clinical settings (Dokoumetzidis et al., 2006). Another relatively simple model developed by Johnson and Swindell (Johnson and Swindell, 1996) presents the concept of maximum absorbable dose (MAD) as an initial guide to determine dissolution characteristics. In this approach, the MAD is calculated by:

$$MAD = S \times K_a \times SIWV \times SITT \quad (3)$$

where S is the solubility at pH 6.5, K_a is the intestinal absorption rate constant, $SIWV$ is the small intestinal water volume, and $SITT$ is the residence time of the drug in the small

intestines. In general, the *SIWV* is considered to be 250 mL and the *SITT* is assumed to be 3 h. This rather simplistic approach has many limitations and can only be utilized as an initial assessment of drug dissolution.

To develop a more comprehensive model, all relevant physicochemical properties must be considered. In addition to solubility, another important factor is the compound's ionization constant or its logarithmic equivalent, the pK_a value. The pK_a values determine the stability, solubility and absorption of compounds under different environmental pH conditions. This is highly relevant because the human body contains inherent pH gradients, especially in the gastrointestinal (GI) tract, which give rise to pH-dependent absorption profiles in vivo (Carlson et al., 1983). The salt form of the drug compound is yet another important factor to be considered. In general, a salt form has a higher dissolution rate than that of its free acid or base form. However, under certain pH conditions in the GI tract, the reverse may also be true (Serajuddin and Jarowski, 1985). Perhaps a more obvious source of effect on dissolution is the particle size. It is commonly recognized that a reduction in particle size would increase surface area and enhance rate of dissolution. It is, however, less well established how particle size reduction affects the dissolution rate. In the study conducted by Johnson and Swindell (Johnson and Swindell, 1996), it was found that the effect of particle size on absorption is dependent on the drug dose and drug solubility. All these factors add to the complexity of the model building process.

2.2. Biopharmaceutical Properties

Drug permeability plays a major role in drug absorption, particularly in orally administered dosage forms. The transcellular permeability (P_m) of a compound is defined as:

$$P_m = \frac{K_p \times D_m}{L_m} \quad (4)$$

where K_p is the membrane-water partition coefficient, D_m is the membrane diffusivity, and L_m is the membrane thickness (Li et al., 2005). Various models have been developed to estimate membrane permeability. One such model is based on the pH-partition theory, which states that the membrane uptake of unionized solutes is favored over the ionized solutes (Shore et al., 1957). For weakly acidic compounds, ionization is suppressed at low pH values, resulting in relatively high absorption rate. At high pH values, equilibrium is shifted towards the ionization of the compound, resulting in decreased membrane permeability. The opposite conclusions can be deduced for weakly basic compounds. It is also predicted that the pH value at which the half maximal absorption occurs is approximately equal to the compound's pK_a value (Winne, 1976). This particular model is not without limitations and deviations have been observed, possibly due to factors such as microenvironmental pH and solubility issues.

Another parameter that may be useful in model development is the oil-water partition coefficient. In particular, octanol-water partition coefficient (P or logP) of neutral or unionized species is often used to provide insight into the ability of compounds to pass through membranes for absorption. Using computer and multiple linear regression, Hansch and Fujita (Hansch and Fujita, 1964) were able to quantitate the structure activity relationships based on lipophilicity. They discovered that in general, a bell-shaped distribution exists between absorption and logP values. Kramer was able to further establish that compounds with logP between 0 and 3 generally had high permeability, and those with logP values less than -1.5 or greater than 4.5 had lower membrane permeability (Kramer, 1999).

It is crucial to point out that although the octanol-water partition coefficient is a good indicator of membrane permeability, by itself it is not a sufficient parameter to predict *in vivo* absorption. Other measures of membrane permeability have been developed, such as absorption potential (AP) and polar surface area (PSA). The concept of absorption potential was developed by Dressman (Dressman et al., 1985) and is defined as:

$$AP = \log \left(\frac{P \times F_{un}}{D_0} \right) \quad (5)$$

where P is the partition coefficient, F_{un} is the fraction of unionized drug at pH6.5, and D_0 is the dose number equal to the ratio of dose concentration to solubility. Studies indicate that AP correlates well with the fraction of drug absorbed. PSA is the surface area of a drug molecule occupied by polar atoms. The PSA value has demonstrated good correlation with the passive transport of molecules through membranes, making it a candidate parameter to include in an *in vivo* absorption model.

2.3. Physiological Properties

Besides physicochemical and biopharmaceutical considerations, physiological conditions are also important factors to consider for successful establishment of IVIVC, since physiological conditions can affect both drug dissolution as well as the rate and extent of drug absorption. In the previous sections, we have demonstrated the influence of pH on solubility, dissolution and membrane permeation. The effect of pH becomes particularly important in the human body, where there is an inherent pH gradient. The most well-known and commonly studied pH gradient is located throughout the GI tract, where it can range from values of 1 – 2 in the stomach to 7 – 8 in the colon. In the small intestine, where the vast majority of orally ingested substances are absorbed, the pH value ranges broadly from 5 to 8. These changes in GI pH profile can alter drug solubility, dissolution, stability and permeability. To further complicate the situation, the physiological environment is constantly adjusting and changing according to normal human activity such as food intake. Another important physiological property for oral dosage forms is the GI transit time, which affects the extent of drug release in the body. Typically, the gastric emptying time for liquids is 1 hour, while for solid materials it is approximately 2 to 3 hours. Consequently, the administration of drugs with liquid or with solid food will result in different drug transit times, leading to variations in extent of drug release. Additionally, food intake stimulates the release of enzymes and digestive fluids, and these may enhance or hinder drug absorption. As we can see, in order to accurately quantitate the relationship between *in vitro* data and *in vivo* response, the mathematical model must account for such changes.

3. Approaches to developing IVIVC models

Under FDA guidance, there are four levels of IVIVC. Level A correlation is the point-to-point correlation between *in vitro* and *in vivo* profiles. This is generally considered as the highest level of correlation and allows prediction of the entire *in vivo* concentration time course from the *in vitro* dissolution profile (Fig. 1). Level B correlation compares a summary parameter from the mean *in vitro* profile with a summary parameter from the mean *in vivo* profile (Fig. 2A). This type of correlation is not considered useful. Level C correlation establishes a single time point correlation between a dissolution parameter and an *in vivo* parameter. An extension of this type of correlation is the multiple Level C correlation, which relates several *in vitro* parameters to *in vivo* parameters at multiple time points (Fig. 2B). Multiple Level C correlations are regarded as more useful than Level C correlations.

Many case studies on different levels of IVIVC have been reported in the literature. In a study by Buch et al., for example, IVIVC for fenofibrate immediate release tablets was investigated (Buch et al., 2010). A linear relationship was established between *in vitro* drug solubility and permeability parameters and the *in vivo* C_{\max} values. In another study, Amann et al. attempted to establish IVIVC for implants consisting of poly(lactic-co-glycolic acid) and the antipsychotic drug risperidone (Amann et al., 2010). Their analysis produced Level B correlation with high R^2 value (0.9585). Although they also obtained high R^2 value when performing linear regression in Level A analysis, the qualitative pattern of the fit indicated that a Level A correlation was not established. As another example, Ochoa et al. evaluated the *in vitro* and *in vivo* release profiles of theophylline formulations produced by one-step melt granulation (Ochoa et al., 2010). They observed Level A correlations between the dissolution and absorption profiles.

From a regulatory viewpoint, it is desirable to establish a Level A correlation. Such IVIVC can then be used to conduct bioequivalence studies between different dissolution profiles and play an important role in manufacturing quality control process. While the literature on Level A modeling and data analysis is extensive and the methods employed vary, in general they all follow common steps towards the establishment of a Level A correlation (Dunne, 2007). The first step is the construction of a functional relationship between the input and output quantities. Next a structural model is developed by connecting the data collected to the functional relationship previously established. The last step involves fitting the model parameters using data analysis.

3.1. Constructing a Functional Relationship

The goal of this step towards the development of an effective IVIVC is to find the relationship between the quantities of interest without considering any collected data. The framework of this approach is the linear time invariant dynamic (LTID) system (Finkelstein and Carson, 1985). LTID system is a system that contains an input $i(t)$ and an output $o(t)$, both as a function of time t . An important characteristic of such a system is that the output corresponding to the input $i_1(t) + i_2(t)$ is equal to the sum of outputs from $i_1(t)$ and $i_2(t)$ calculated separately. In addition, shifting the input at time t by a period of Δt will result in a similar shift of the output. In other words, $i(t + \Delta t)$ has an output of $o(t + \Delta t)$. Having established these principles, it is easy to derive the following equation for all LTID systems:

$$o(t) = \int_0^t i(\tau) r(t - \tau) d\tau \quad (6)$$

where the function $r(t)$ represents the functional characteristic of the system and $i(\tau)$ is the unit input at an infinitely short period of time. This integral is known as the convolution integral. The purpose of forming an IVIVC is to use information from *in vitro* dissolution to predict the *in vivo* outcome. Usually *in vitro* dissolution is represented by the fraction of the dosage form dissolved, designated here by the function $F_1(\theta_1, t)$, where θ_1 consists of all the different parameters that contribute to the *in vitro* dissolution of the dosage form. Similarly, we can designate a function in the form of $F_2(\theta_2, t)$ to represent the fraction of drug dissolved *in vivo*, where θ_2 represents all parameters affecting the *in vivo* dissolution of the dosage form. In clinical settings, however, this function is rather difficult to observe directly. To solve this issue, the plasma drug concentration is used instead of *in vivo* drug dissolution. If we denote plasma drug concentration at time t as $C(t)$, using the convolution integral we can obtain the following equation:

$$C(t) = \int_0^t i(\tau) r(t - \tau) d\tau \quad (7)$$

Here the input function $i(t)$ describes changes in the rate at which the drug enters the system. Since it is partly dependent on *in vivo* drug dissolution, we can express this function as:

$$i(t) = f_3(\theta_3, t, F_2(\theta_2, t)) \quad (8)$$

where θ_3 consists of the parameters that affect the rate at which drug enters the system besides *in vivo* drug dissolution, such as drug absorption, distribution, metabolism and elimination. Equation 7 also contains the characteristic unit impulse response function $r(t)$, which in itself is dependent on parameters that we inclusively define as θ_4 . Therefore:

$$r(t) = f_4(\theta_4, t) \quad (9)$$

Information about this function is often collected by inputting a unit input of infinitely small duration into the system and examining the corresponding output. The unit input can be of various dosage forms, such as intravenous and oral (Balan et al., 2001; Sirisuth et al., 2002). Depending on the type of dosage form administered, the parameters included in θ_3 and θ_4 may change. For example, if the unit input is administered intravenously, drug absorption would be bypassed and become an inherent part of the input. On the other hand, if the unit input is administered in the oral form, absorption would remain to be characterized.

The final step is the construction of a functional relationship between the input *in vitro* dissolution and the output *in vivo* dissolution. That is, we must establish the following relationship:

$$F_2(\theta_2, t) = f_5(\theta_5, t, F_1(\theta_1, t)) \quad (10)$$

This equation is what we ultimately want to achieve in IVIVC model development. Utilizing the approach outlined above, many models have been derived to describe the unit impulse response function $r(t)$, the input function $i(t)$, the *in vitro* dissolution function $F_1(\theta_1, t)$ and the *in vivo* drug dissolution function $F_2(\theta_2, t)$. As mentioned previously, $r(t)$ and $i(t)$ models take on different forms depending on the pharmacokinetics of the LTID system. For example, for one compartmental pharmacokinetics model without drug absorption in the LTID system would have a different $r(t)$ than a multi-compartment pharmacokinetics model without drug absorption in the LTID system (Table 1). For processes that do not include absorption as part of the LTID system, the input function contains both absorption and *in vivo* dissolution. If the model does include absorption in the LTID system, the input function is simply the *in vivo* drug dissolution rate. The main disadvantage associated with using these models for $r(t)$ is that assumptions are made about the structure of the LTID system. Alternatively, a deconvolution approach can be used but this model contains more parameters and is therefore more complex.

Similarly, various functional models can be derived for $F_1(\theta_1, t)$ and $F_2(\theta_2, t)$ (Table 2 and 3) (Bigora et al., 1997; Buchwald, 2003; Langenbucher, 2003; Mendell-Harary et al., 1997; Polli et al., 1996). The models listed in Table 2 have a common characteristic of predicting zero dissolution at time zero and complete dissolution at sufficient time t . By introducing a parameter that represents the degree of dissolution, these models can easily be modified to account for incomplete dissolution. Table 3 lists some of the commonly used models that relate *in vivo* drug dissolution to *in vitro* dissolution. However, a major limiting factor of these models is the assumption that *in vitro* – *in vivo* relationship does not vary with time.

3.2. Constructing a Structural Model

The functional relationship described previously does not take into consideration any information gathered from actual data. The construction of a structural model connects the data collected to the functional models established earlier. The structural model can also be seen as a statistical model that forms a framework for parameterization, which is generally the last step in the development of a Level A IVIVC. Generally, the following approach is taken towards structural model development. In a previous statement, we denoted the plasma drug concentration at time t to be $C(t)$. For any given data set, it contains a value $Y(t)$ such that it is an approximation of the true value $C(t)$. Statistically speaking, $C(t)$ is the true value of plasma drug concentration at time t ; it is a value that can never be precisely determined by experiments due to the presence of inevitable random errors. As a result, we can only estimate $C(t)$ by the value of $Y(t)$. The process of defining the statistical properties of $Y(t)$ is the structural modeling process. Similarly, we can define a function that is capable of approximating the true value of *in vitro* dissolution data at time t .

In constructing a viable structural model, some form of data transformation may be necessary. For example, based on the previous definitions and properties of $C(t)$ and $Y(t)$, we can derive a simple relationship such that:

$$Y(t) = C(t) + \varepsilon_1 \varepsilon_1 \mathcal{N}(0, \sigma_1^2) \quad (11)$$

The term ε_1 represents the random differences between the true value $C(t)$ and the estimate value $Y(t)$. The errors are normally distributed around a mean of 0 and have a constant variance of σ_1^2 . From this equation we can also see that $Y(t)$ is also random and normally distributed, with both positive and negative values. However, we know that plasma concentration values cannot be negative, therefore a transformation of the data is necessary to ensure normality. One common transformation is to assume that the logarithm of plasma concentration is normally distributed such that:

$$\ln(Y(t)) = \ln(C(t)) + \varepsilon_2 \varepsilon_2 \mathcal{N}(0, \sigma_2^2) \quad (12)$$

However, this transformation presents the problem that equations 11 and 12 are not equivalent if ε_1 and ε_2 are not both equal to 0. Furthermore, the constant variance assumption in equation 11 may not hold as the function undergoes logarithmic transformations and vice versa. Other non-linear transformations will encounter similar situations. This clearly demonstrates that depending on the assumptions made and the methods used construct a structural model, the same functional relationship may result in different structural models, subsequently leading to different parameterization and predictions of *in vivo* results (Dunne, 2007).

Besides data transformations, there are other issues that must be taken into account when developing a structural model. One common practice is to collect *in vitro* and *in vivo* data across multiple dosage units and subjects at each time point, then averaging the data to construct a model (Eddington et al., 1998). This practice may lead to a loss in data information. In addition, it can be shown by simple simulation that a curve constructed from averages is not the same as curves constructed from averaging individual sets of data (Dunne, 2007). Another factor that needs to be considered is the discrepancy between theoretical and measured values. As we know the theoretical fraction of drug dissolved *in vitro* or *in vivo* should be a value between 0 and 1. In practice, the measured values may

exceed 1 due to sampling errors or discrepancy between label claim and actual dose. An effective structural model may need to account for such deviations.

3.3. Model Fitting and Parameterization

After data collection and the development of a structural model, the unknown constants in the model have to be estimated. There are a number of statistical methods used for parameterization, including the method of maximum likelihood, the method of least squares and Bayesian analysis. The statistical characteristics of the data collected can be used to select the appropriate method for parameterization. For example, for a set of data values that are uncorrelated and have constant variance, the method of unweighted least squares is suitable; however, for data values that are correlated and have non-constant variance, weighted least squares have to be used (Kutner et al., 2004). Regardless of the method used, the ultimate goal is to produce a model that is in best agreement with the data collected. Previously, we mentioned the possibility of multiple structural models arising from a single functional relationship; during parameterization, different structural models will produce different parameter estimates. Thus it is important to be aware that the same functional relationship established early on in the process of IVIVC development can produce varying IVIVC models.

4. Applications of IVIVC

4.1. Biopharmaceutical Classification System

The biopharmaceutical classification system (BCS) is a way to categorize drug compounds based on their solubility and permeability properties. Under the BCS, drug substances can be grouped into four classes: Class 1 compounds are highly soluble and highly permeable; Class 2 substances have high permeability but relatively low solubility; Class 3 compounds are highly soluble but not very permeable; and Class 4 drug substances have both low solubility and low permeability. In general, it is recognized that the successful development and application of an IVIVC require dissolution to be the rate-limiting step in the process of drug administration and absorption. For Class 1 compounds, there are no rate-limiting steps for drug absorption, with the possible exception of immediate release dosage forms, for which gastric emptying could potentially become the rate-limiting step (Modi, 2007). For Class 2 compounds dissolution is the rate-limiting step in absorption, therefore the establishment of IVIVC is expected. For Class 3 compounds, IVIVC is generally regarded as unlikely but may be possible depending on the relative rates of dissolution and intestinal transit. For Class 4 compounds IVIVC is highly unlikely. Classification according to the BCS will enable early determination of whether IVIVC can be developed for a certain drug candidate.

4.2. Biowaivers

A biowaiver is an exemption granted by the FDA that allows *in vivo* bioavailability and/or bioequivalent studies to be avoided. A predictive and reliable IVIVC model can serve as a basis for biowaivers, allowing reductions in time and costs during pharmaceutical product development. For immediate release dosage forms, the successful development of IVIVC models may be limited to Class 2 and Class 3 compounds classified under the BCS, thereby restricting the application of biowaivers to these classes of drug compounds. However, according to FDA guidelines biowaivers can also be requested for Class 1 compounds provided the drugs are solubilized in the gastric fluid sufficiently rapidly that gastric emptying does not become the rate-limiting step. The situation for extended release (ER) dosage forms is more complex, since the factors considered in the BCS (i.e. solubility and intestinal permeability) are insufficient to predict the rate and extent of dissolution for ER drugs. Despite these limitations, the FDA has published important guidelines for

establishing IVIVC for ER dosage forms. Readers should refer to the document “*FDA Guidance for Industry – ER oral dosage forms: development, evaluation, and application of IVIVCs*” (FDA, 1997) and “*FDA Guidance for Industry – Waiver on in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics classification systems*”(FDA, 2005) for more detailed information.

4.3. Non-oral Dosage Forms

Currently, regulatory guidance for IVIVC is mainly focused on oral dosage forms. However, similar principles of developing IVIVCs can be applied to non-oral dosage forms, with certain modifications to adjust for different modes and durations of drug delivery. Perhaps one of the most challenging aspects of developing IVIVCs non-oral drug delivery systems is how to design *in vitro* studies such that the *in vivo* behavior is reflected as much as possible. For example, it is difficult to apply classical IVIVC to drug-eluting stents because it is a local delivery system, not a systemic delivery system like oral dosage forms. Several publications have attempted to correlate *in vitro* pharmacokinetics of paclitaxel (Finkelstein et al., 2003) and dexamethasone (Lincoff et al., 1997) loaded stents with *in vivo* delivery into the artery wall with limited success. Another difficulty that may hinder the design of appropriate *in vitro* studies is the lack of suitable dissolution media that reflect the *in vivo* environment non-oral delivery systems are subjected to. This is particularly the case for implanted drug delivery devices and liposomal products. Liposomal formulations have traditionally demonstrated poor correlation between *in vitro* and *in vivo* performance, possibly due to the physiological presence of a lipid membrane ‘sink’ to which released drugs may bind (Shabbits et al., 2002). To circumvent this problem, a novel drug release assay has been developed using excess multilamellar vesicles (Shabbits et al., 2002). This method demonstrated improved correlation between *in vitro* data and *in vivo* release of doxorubicin, verapamil and ceramide.

5. Conclusions

The development of a predictive and reliable IVIVC model is a complex process. Professor Takeru Higuchi, a pioneer in this field, developed one of the most important controlled release equations, known as the Higuchi's Equation. Since then this well-known and widely used equation has influenced drug delivery development and provided groundwork for subsequent IVIVC modeling. This review attempts to elucidate some of the general principles involved in the construction of IVIVC. Before the commencement of model building, it is important to consider the factors that may contribute to the *in vitro* and *in vivo* performance of the drug compounds. Since by definition the IVIVC is a mathematical model, various algebraic, calculi and statistical methods are employed in its development. Once a reliable IVIVC model has been developed, it can serve as regulatory guidance for pharmaceutical industry. With justified modifications, its applications can be expanded to include more dosage forms beside oral dosage forms. Currently numerous studies have been conducted that demonstrate the existence of relationships between *in vitro* dissolution and *in vivo* release data. However, most of these studies fail to provide mathematical models that describe these relationships. What's needed is not only more extensive research into IVIVC, but also better mathematical methods and simulation techniques.

References

- Amann LC, Gandal MJ, Lin R, Liang YL, Siegel SJ. In Vitro-In Vivo Correlations of Scalable PLGA-Risperidone Implants for the Treatment of Schizophrenia. *Pharm. Res.* 2010; 27:1730–1737. [PubMed: 20422263]

- Balan G, Timmins P, Greene DS, Marathe PH. In vitro-in vivo correlation models for metformin after administration of modified release oral dosage forms to healthy human volunteers. *J. Pharm. Sci.* 2001; 90:1176–1185. [PubMed: 11536222]
- Bigora, S.; Piscitelli, D.; Dowell, J. Use of nonlinear mixed effects modelling in the development of in vitro - in vivo correlations. In: Young, D.; Devane, JG.; Butler, J., editors. *Advances in Experimental Medicine and Biology*. Plenum Press; New York: 1997. p. 207-215.
- Buch P, Holm P, Thomassen JQ, Scherer D, Branscheid R, Kolb U, Langguth P. IVIVC for Fenofibrate Immediate Release Tablets Using Solubility and Permeability as In Vitro Predictors for Pharmacokinetics. *J. Pharm. Sci.* 2010; 99:4427–4436. [PubMed: 20737642]
- Buchwald P. Direct, differential equation based in vitro - in vitro correlation method. *J. Pharm. Pharmacol.* 2003; 55:495–504. [PubMed: 12803771]
- Carlson JA, Mann HJ, Canafax DM. Effect of pH on disintegration and dissolution of ketoconazole tablets. *Am. J. Hosp. Pharm.* 1983; 40:1334–1336. [PubMed: 6310994]
- Dokoumetzidis A, Papadopoulou V, Macheras P. Analysis of dissolution data using modified versions of Noyes-Whitney equation and the Weibull function. *Pharm. Res.* 2006; 23:256–261. [PubMed: 16421665]
- Dressman JB, Amidon GL, Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. *J. Pharm. Sci.* 1985; 74:588–589. [PubMed: 4020642]
- Dunne, A. Approaches to developing in vitro-in vivo correlation models. In: Chilukuri, DM.; S, G.; Young, D., editors. *Pharmaceutical Product Development*. Informa Healthcare USA; New York: 2007. p. 47-70.
- Eddington ND, Marroum P, Uppoor R, Hussain A, Augsburg L. Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. *Pharm. Res.* 1998; 15:466–473. [PubMed: 9563079]
- Edwards LJ. The dissolution and diffusion of aspirin in aqueous media. *Trans. Faraday Soc.* 1951; 47:1191–1210.
- The Food and Drug Administration, U.S.. Extended release solid dosage forms: development, evaluation and application of in vitro/in vivo correlations. 1997. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070239.pdf>
- The Food and Drug Administration, U.S.. FDA Guidance for Industry. - Waiver on in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics classification systems. 2005. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf>
- Finkelstein A, McClean D, Kar S. Local drug delivery via coronary stent with programmable release pharmacokinetics. *Circulation.* 2003; 107:777–784. [PubMed: 12578884]
- Finkelstein, L.; Carson, ER. *Mathematical modelling of dynamic biological systems*. 2nd ed. John Wiley & Sons; New York: 1985.
- Hansch C, Fugita T. Rho-sigma-pi analysis. A method for the correlation of biological activity and chemical structure. *J. Am. Chem. Soc.* 1964; 86:1616–1626.
- Johnson KC, Swindell AC. Guidance in the setting of drug particle size specification to minimize variability in absorption. *Pharm. Res.* 1996; 13:1795–1798. [PubMed: 8987073]
- Kramer SD. Absorption prediction from physicochemical parameters. *Pharm. Sci. Technol.* 1999; 2:373–380. Today.
- Kutner, M.; Nachtsheim, C.; Neter, J.; Li, W. *Applied linear statistical models*. 5th ed. McGraw-Hill; New York: 2004.
- Langenbucher F. Handling of computational in vitro/in vivo correlation problems by Microsoft Excel II. Distribution of functions and moments. *Eur. J. Pharm. Biopharm.* 2003; 55:77–84. [PubMed: 12551707]
- Li SF, He HD, Parthiban LJ, Yin HQ, Serajuddin ATM. IVIVC considerations in the development of immediate-release oral dosage form. *J. Pharm. Sci.* 2005; 94:1396–1417. [PubMed: 15920764]

- Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. *J. Am. Coll. Cardiol.* 1997; 29:808–816. [PubMed: 9091528]
- Mendell-Harary, J.; Dowell, J.; Bigora, S. Nonlinear in vitro - in vivo correlations. In: Young, D.; Devane, JG.; Butler, J., editors. *Advances in Experimental Medicine and Biology*. Plenum Press; New York: 1997. p. 199-206.
- Modi, NB. In vitro-in vivo correlation. In: Chilukuri, DM.; S, G.; Young, D., editors. *Pharmaceutical Product Development*. Informa Healthcare USA; New York: 2007. p. 107-123.
- Nelson E. Solution rate of theophylline salts and effects from oral administration. *J. Am. Pharm. Assoc. Sci.* 1957; 46:608–614.
- Ochoa L, Igartua M, Hernandez RM, Solinis MA, Gascon AR, Pedraz JL. In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: Level A in vitro-in vivo correlation. *Eur. J. Pharm. Biopharm.* 2010; 75:232–237. [PubMed: 20159037]
- Polli JE, Crison JR, Amidon GL. Novel approach to the analysis of in vitro-in vivo relationships. *J. Pharm. Sci.* 1996; 85:753–760. [PubMed: 8819002]
- Serajuddin ATM, Jarowski CI. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts. *J. Pharm. Sci.* 1985; 82
- Shabbits JA, Chiu GNC, Mayer LD. Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. *J. Control. Release.* 2002; 84:161–170.
- Shore PA, Brodie BB, Hogben CAM. The gastric secretion of drugs: a pH partition hypothesis. *J. Pharmacol. Exp. Ther.* 1957; 119:361–369.
- Sirisuth N, Augsburger LL, Eddington ND. Development and validation of a nonlinear IVIVC model for a diltiazem extended release formulation. *Biopharm. Drug Dispos.* 2002; 23:1–8.
- Winne D. Shift of pH-absorption curves. *J. Pharmacok. Biopharm.* 1976; 5:53–94.




Figure 1. Example of Level A IVIVC. (A) *In vitro* dissolution profiles of slow (square), medium (circle), or fast drug formulations (triangle). (B) *In vivo* studies provide plasma drug concentration of each formulation (gray lines), which can be converted to fractional absorption profile (black lines) by deconvolution. (C) Level A IVIVC can be derived from the fractional dissolution *in vitro* and the fractional absorption *in vivo*. Figure shows a linear correlation, but FDA accepts non-linear correlation as well.




Figure 2.
Example of Level B (A) and Level C IVIVC (B).

Table 1

Some of the functions used to describe the unit impulse function.

Parameters	One compartment	Two compart
<p>V: apparent volume of distribution</p> <p>k_e: first order elimination rate constant</p> <p>k_a: first order absorption rate constant</p> <p>k_{12}: rate constant for transfer from central to peripheral compartment</p> <p>k_{21}: rate constant for transfer from peripheral to central compartment</p>	<ul style="list-style-type: none"> • Single compartment = body • Even distribution of drug throughout body • Only applicable for rapidly distributed drug 	<ul style="list-style-type: none"> • C • on • (c • S • c
<p>Without absorption</p> <ul style="list-style-type: none"> • Very rapidly absorbed drug (almost ideal) 	$r(t) = \frac{1}{V} e^{(-k_e t)}$	$r(t) = \frac{1}{V(k_e)}$
<p>With absorption</p> <ul style="list-style-type: none"> • Commonly applicable • Severely influenced by physicochemical, biopharmaceutical, and physiological factors 	$r(t) = \frac{k_a}{V} \left[\frac{k_{21} - k_a}{(\lambda_1 - k_a)(\lambda_2 - k_a)} e^{(-k_a t)} + \frac{k_{21} - \lambda_1}{(k_a - \lambda_1)(\lambda_2 - \lambda_1)} e^{(-\lambda_1 t)} + \frac{k_{21} - \lambda_2}{(k_a - \lambda_2)(\lambda_1 - \lambda_2)} e^{(-\lambda_2 t)} \right]$	$r(t) = \frac{A}{V} e^{(-\lambda t)}$

$\lambda_1 + \lambda_2 = k_e + k_{12} + k_{21}$; $\lambda_1 \lambda_2 = k_e k_{21}$; $A = (k_{21} - \lambda_1)/(\lambda_2 - \lambda_1)$.

Table 2

Some of the functions describing *in vitro* drug dissolution.

Description	Function
Exponential	$F_1(\theta_1, t) = 1 - e^{-\theta_1 t}$
Weibull	$F_1(\theta_1, t) = 1 - e^{-(\theta_1 t)^{\theta_{12}}}$
Logistic	$F_1(\theta_1, t) = \frac{e^{(\theta_{11} + \theta_{12} \log(t))}}{1 + e^{(\theta_{11} + \theta_{12} \log(t))}}$
Hill	$F_1(\theta_1, t) = \frac{t^{\theta_{11}}}{\theta_{12} + t^{\theta_{11}}}$

θ_{1i} , ($i = 1$ and 2): parameter θ_1 at observation times t_1 and t_2 .

Table 3

Some of the functions describing the relationship between *in vivo* and *in vitro* drug dissolution.

Description	Function
Identity	$F_2(\theta_2, t) = F_1(\theta_1, t)$
Linear	$F_2(\theta_2, t) = \theta_{51} + \theta_{52}F_1(\theta_1, t)$
Sigmoid	$F_2(\theta_2, t) = \theta_{51} + \frac{\theta_{52}F_1(\theta_1, t)^{\theta_{53}}}{\theta_{54} + F_1(\theta_1, t)^{\theta_{53}}}$
Higuchi	$F_2(\theta_2, t) = (\theta_{51}F_1(\theta_1, t))^{0.5}$
Hixon-Crowell	$F_2(\theta_2, t) = \theta_{51} - (\theta_{51}^{0.33} - \theta_{52}F_1(\theta_1, t))^3$
Weibull	$F_2(\theta_2, t) = \theta_{51} - \theta_{52}e^{(-\theta_{53}(F_1(\theta_1, t)))^{\theta_{54}}}$

θ_{5j} ($i = 1, 2, 3, 4$): parameter θ_5 (see equation 10) at observation times t_1, t_2, t_3, t_4 .